Skip to main content

Table 1 The patients’ characteristics and laboratory parameters at CVVH start between the two groups

From: Feasibility and efficacy of modified fixed citrate concentration protocol using only commercial preparations in critically ill patients: a prospective cohort study with a historical control group

Variables Fixed group (n = 66) Titrated group (n = 64) P value
Age, years, mean (SD) 62.7 (18.4) 64.1 (17.6) 0.379
Female gender, n (%) 24 (36.4) 22 (34.4) 0.813
Body weight, kg, median (IQR) 69.2 (61.5–74.3) 70.5 (63.5–74.5) 0.852
Comorbidities, n (%)
 Chronic kidney disease a 13 (19.7) 12 (18.8) 0.891
 Dialysis-dependent 6 (9.1) 2 (3.1) 0.157
 Diabetes mellitus 14 (21.2) 17(26.6) 0.474
 Hypertension 19 (28.8) 16 (25.0) 0.626
 Liver dysfunction b 1 (1.5) 1 (1.6) 0.983
 Cardiac insufficiency c 3 (4.5) 3 (4.7) 0.969
Severity of illness
 APACHE II score, mean (SD) 23.1 (6.8) 22.7 (6.4) 0.541
 SOFA score, mean (SD) 8.0 (2.7) 8.3 (2.3) 0.672
 Vasopressors, n (%) 58 (87.9) 57 (89.1) 0.833
 Mechanical ventilation, n (%) 60 (90.9) 58 (90.6) 0.955
Indication for CVVH, n (%)
 Sepsis-induced AKI 54 (81.8) 55 (85.9) 0.523
 Fluid overload 5 (7.6) 5 (7.8) 0.960
 Tumorlysis syndrome 4 (6.1) 2 (3.1) 0.425
 Others 3 (4.5) 2 (3.1) 0.674
Application of LMWH, n (%) 19(28.8) 24(37.5) 0.352
Laboratory parameters
 Hemoglobin, g/L, mean (SD) 89.1 (19.2) 85.5 (19.7) 0.573
 Platelet count, 109/L, median (IQR) 74.1 (50.7–97.5) 81.5 (60.8–102.2) 0.153
 APTT, S, mean (SD) 42.6 (8.7) 43.2 (8.1) 0.754
 PT, S, mean (SD) 14.0 (2.7) 14.6 (2.3) 0.805
 Serum albumin, g/L, mean (SD) 23.3 (2.4) 24.7 (3.5) 0.672
 Bilirubin, mmol/l, mean (SD) 29.4 (7.5) 27.0 (10.8) 0.718
 ALT, U/L, mean (SD) 68 (28.8) 56 (25.5) 0.182
 Creatinine, μmol/l, median (IQR) 229 (169–559) 240 (143–497) 0.756
 Urea, mmol/l, median (IQR) 33.9 (15.6) 30.8 (14.7) 0.347
 Lactate, mmol/l, median (IQR) 4.8 (2.7–6.8) 4.5 (3.1–6.3) 0.498
 ICU death at 28 days, n (%) 20 (30.3) 22 (34.4) 0.239
  1. Abbreviations: AKI acute renal injury, ALT Alanine Aminotransferease, APACHE, acute physiology and chronic health evaluation, APTT activated partial thromboplastin time, CVVH continuous veno-venous hemofiltration, ICU Intensive Care Unit; IQR interquartile range, LMWH low molecular weight heparin, PT prothrombin time, RCA regional citrate anticoagulation, SD standard deviation, SOFA Sequential Organ Failure Assessment
  2. a Chronic kidney disease defined as stage 3–5 according to Kidney Disease Improving Global outcome in 2012;
  3. b liver dysfunction defined as Child-pugh B-C stage
  4. c Chronic cardiac insufficiency defined of stage III-IV according to New York Heart Association
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us